Methods of treating hemophilia or von willebrand disease with p-selectin

• US 7,387,777 B2
• Filed: 02/19/2004
• Issued: 06/17/2008
• Est. Priority Date: 05/19/2000
• Status: Expired due to Fees

• Current Assignee: Center For Blood Research Incorporated
• Original Assignee: Center For Blood Research Incorporated
• Inventors: Andre, Patrick, Hrachovinova, Ingrid, Wagner, Denisa D., Hartwell, Daqing W.
• Primary Examiner(s): Gambel; Phillip
• Application Number:
  US10/782,456
• Publication Number:
  US 20040265311A1
• Time in Patent Office: 1,580 Days
• Field of Search: None
• US Class Current: 424/134.1
• CPC Class Codes: A61K 38/178 Lectin superfamily, e.g. selectins
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: G01N 2333/70564 Selectins, e.g. CD62
• CPC Class Codes: G01N 33/86 involving blood coagulating time or factors, or their receptors

Abstract

The present invention identifies P-selectin as a modulator of hemostasis. Accordingly, the present invention relates to methods for the identification and use of modulators of P-selectin activity as modulators of hemostasis. The invention also relates to methods and compositions for the diagnosis and treatment of hemostatic disorders, including, but not limited to, hemorrhagic disorders and thrombotic disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hemostatic conditions, and for the identification of subjects exhibiting a predisposition to such conditions. In addition, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of a hemostatic or vascular disorders, and for monitoring the efficacy of compounds in clinical trials.

Claims

1. A method for treating hemophilia or von Willebrand'"'"'s disease in a subject, said method comprising administering to said subject an inducer of P-selectin activity selected from the group consisting of a soluble P-selectin polypeptide and a P-selectin fusion protein, such that the hemophilia or von Willebrand'"'"'s disease is treated or prevented.

2. The method of claim 1, wherein said hemophilia is hemophilia A.

3. The method of claim 1, wherein said hemophilia is hemophilia B.

4. The method of claim 1, wherein the inducer of P-selectin activity increases the level of soluble P-selectin polypeptide in the plasma of the subject.

5. The method of claim 1, wherein the inducer of P-selectin activity is a fusion protein.

6. The method of claim 1, wherein the P-selectin fusion protein comprises a soluble P-selectin polypeptide operatively linked to an immunoglobulin.

7. The method of claim 6, wherein the immunoglobulin is a human IgG 1, and the Fc region of the immunoglobulin is fused to the C-terminus of at least one soluble P-selectin polypeptide.